亚盛医药Ascentage Pharma（AAPG）2024年20-F年度报告「NASDAQ」（英文版）（367页）.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 20-F(Mark One)REGISTRATION STATEMENT PURSUANT TO SECTION 12(b)OR(g)OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended Decembe

2、r 31,2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from _ to _ Commission file numb

3、er 333-284064 ASCENTAGE PHARMA GROUP INTERNATIONAL(Exact name of Registrant as specified in its charter)Not Applicable Cayman Islands(Translation of Registrants name into English)(Jurisdiction of incorporation or organization)68 Xinqing RoadSuzhou Industrial ParkSuzhou,JiangsuChina(Address of princi

4、pal executive offices)Thomas J.KnappAscentage Pharma Group Inc.700 King Farm Blvd,Suite 510Rockville,Maryland 20850(301)520-1026 (Name,Telephone,E-mail and/or Facsimile number and Address of Company Contact Person)Securities registered or to be registered pursuant to Section 12(b)of the Act.Title of

5、 each class Trading Symbol(s)Name of each exchange on which registeredAmerican depositary shares(each representing four ordinary shares,no parvalue per share)AAPG Nasdaq Global Market Securities registered or to be registered pursuant to Section 12(g)of the Act.None Securities for which there is a r

6、eporting obligation pursuant to Section 15(d)of the Act.None Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of the period covered by the annualreport:348,266,581 Ordinary Shares,par value US$0.0001 per share,as of March 1,2025 Indi